Growth hormone treatment of infants with chronic kidney disease: requirement, efficacy, and safety

Haffner, Dieter; Fischer, Dagmar‐Christiane

doi:10.1007/s00467-009-1192-z

Cited by 13 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Catch-up growth is not noted. A late onset and short duration of puberty result in a further important loss of height SDS during the pubertal growth phase [57,58].…”

Section: Growth Hormone Therapymentioning

confidence: 99%

Growth and body composition in very young SGA children

2010

View full text Add to dashboard Cite

Infants with a very low birth weight are at risk of a reduced number of nephrons predisposing to kidney disorder, hypertension, and metabolic syndrome. Approximately 3% of infants are born small for gestational age (SGA), defined as birth weight and/or length at least 2 SD below the mean for gestational age (GA), independently of whether these children are born prematurely or at term. About 10% of these children do not show postnatal catch-up growth and remain of short stature during childhood. Most of these infants are not growth hormone (GH)-deficient, but may have GH resistance. Although GH-resistant, the majority of patients benefit from GH therapy, normalize height during childhood, maintain a normal growth velocity during puberty, and attain a normal adult height. To date, GH has been shown to be safe and no significant adverse effects have been demonstrated. Children with congenital chronic kidney disease (CKD) are born with subnormal birth weight and length and about 25% are born SGA. Shortness and need for GH treatment is highly correlated with weight at birth and gestational age. Primary renal disorders modify the response to GH treatment. Analysis of whether SGA is an additional risk factor for CKD regarding the development of hypertension, metabolic syndrome and cardiovascular complications is required.

show abstract

“…Catch-up growth is not noted. A late onset and short duration of puberty result in a further important loss of height SDS during the pubertal growth phase [57,58].…”

Section: Growth Hormone Therapymentioning

confidence: 99%

Growth and body composition in very young SGA children

2010

View full text Add to dashboard Cite

show abstract

“…Additionally, sustaining adequate nutrition is further hampered as this patient group tend to suffer catabolic phases related to infectious episodes, recurrent vomiting secondary to gastro-oesophageal reflux, chronic dehydration [6] and uraemic effects upon gut motility [7]. Nevertheless, Kari et al [8] have demonstrated excellent growth in this patient group with early enteral feeding via nasogastric or gastrostomy tubes.…”

Section: Growth and Pth Through The Phasesmentioning

confidence: 94%

Parathyroid hormone and growth in chronic kidney disease

Waller

2010

Pediatr Nephrol

View full text Add to dashboard Cite

Growth failure is common in children with chronic kidney disease, and successful treatment is a major challenge in the management of these children. The aetiology is multi-factorial with "chronic kidney disease-metabolic bone disorder" being a key component that is particularly difficult to manage. Parathyroid hormone is at the centre of this mineral imbalance, consequent skeletal disease and, ultimately, growth failure. When other aetiologies are treated, good growth can be achieved throughout the course of the disease when parathyroid hormone (PTH) levels are in the normal range or slightly elevated. A direct correlation between PTH levels and growth has not been convincingly established, and the direct effect of PTH on growth has not been adequately described; furthermore, direct actions of PTH on the growth plate are unproven. The effects of PTH on growth stem from the pivotal role that PTH plays in the development of renal osteodystrophy. In severe secondary hyperparathyroidism, the growth plate is altered and growth is affected. At the other end of the spectrum, with an over-suppressed parathyroid gland, the rate of bone turnover and remodelling is markedly diminished, and some data suggest this is associated with poor growth. Most of the data available suggests that avoiding the development of significant bone disease through the strict control of PTH levels permits good growth. Absolute optimal ranges for PTH that maximise growth or minimise growth failure are not yet established.

show abstract

“…La introducción de terapias derivadas de la medicina génica permite hoy en día que en la mayoría de los casos el paciente urémico en diálisis no sea diferente de sus pares, y que el período de su vida en que se someten a diálisis peritoneal o hemodiálisis, en espera de un trasplante renal, sea compatible con una vida normal. La introducción de sistemas automatizados de diálisis peritoneal como la Home Choice® (Baxter Healthcare Co), la eritropoyetina humana recombinante (EPO) de vida media corta, mediana y prolongada, la 1,25 (OH) 2 VitD o calcitriol, medicamentos fi jadores de fósforo intestinal, calcimiméticos y fi nalmente la hormona de crecimiento (GH), son la base de un tratamiento médico altamente favorable durante el período en diálisis [4][5][6][7][8] .…”

Section: Introductionunclassified

Enfermedad renal crónica en pediatría y nuevos marcadores moleculares

Sch

2012

Rev. chil. pediatr.

View full text Add to dashboard Cite

Growth hormone treatment of infants with chronic kidney disease: requirement, efficacy, and safety

Abstract: Growth failure is still a

Cited by 13 publications

References 25 publications

Growth and body composition in very young SGA children

Growth and body composition in very young SGA children

Parathyroid hormone and growth in chronic kidney disease

Enfermedad renal crónica en pediatría y nuevos marcadores moleculares

Contact Info

Product

Resources

About